EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease - European Journal of Cancer: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non–small-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting.
Highlights:
- •The majority aimed to cure sOM NSCLC patients.
- •The maximum number of metastases considered in sOM-d was 42% ≤ 3 and 17% ≥ 5.
- •Most considered only ≤3 involved organs (excluding primary).
- •Few counted mediastinal lymph node as a metastatic site.
- •The preferred primary outcome for sOM clinical trials was overall survival.
Bibliographic reference: Levy A, Hendriks LEL, Berghmans T, et al. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. Eur J Cancer. 2019;122:109-114. Available at: https://doi.org/10.1016/j.ejca.2019.09.012.
